Significant Ownership of Avidity Partners Management LP
- Signature - Title
- By: Avidity Partners Management (GP) LLC, its general partner, By: /s/ Michael Gregory - Michael Gregory, Managing Member
- Location
- Dallas, TX
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Avidity Partners Management LP.
Follow Filing Activity
Follow Avidity Partners Management LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Avidity Partners Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IMUX | Immunic, Inc. | Common Stock, $0.0001 par value | 9.9% | $15,493,835 | +$10,277,489 | 13,958,410 | +197% | Avidity Partners Management LP | 17 Feb 2026 |
| CNTX | Context Therapeutics Inc. | Common Stock, par value $0.001 per share | 9.9% | $8,913,522 | +$72,083 | 9,200,580 | +0.82% | Avidity Partners Management LP | 30 Sep 2025 |
| SCYX | Scynexis, Inc. | Common Stock, par value $0.001 per share | 9.9% | $2,921,533 | -$59,527 | 4,426,565 | -2% | Avidity Partners Management LP | 31 Dec 2025 |
| SYRS | Syros Pharmaceuticals, Inc. | Common Stock, $0.001 par value | 7.6% | $61,441 | 2,048,020 | Avidity Partners Management LP | 31 Dec 2024 | ||
| KZR | Kezar Life Sciences, Inc. | Common Stock, par value $0.001 per share | 6.9% | $397,054 | 502,600 | Avidity Partners Management LP | 31 Dec 2024 | ||
| CATX | Perspective Therapeutics, Inc. | Common Stock, $0.001 par value | 5.3% | $29,523,995 | +$15,659,798 | 6,049,999 | +113% | Avidity Partners Management LP | 20 Feb 2026 |
| DNTH | Dianthus Therapeutics, Inc. | Common Stock, $0.001 par value | 4.9% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| KZR | Kezar Life Sciences, Inc. | Common Stock, par value $0.001 per share | 0% | $0 | 0 | Avidity Partners Management LP | 30 Sep 2025 |
Schedules 13D/G Reported by Avidity Partners Management LP:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.